Study #2024-0488
A phase 1a/1b, first-in-human, multicenter study to assess the efficacy and safety of RGT61159 for treatment of patients with relapsed/refractory adenoid cystic carcinoma (ACC) or colorectal carcinoma (CRC)
MD Anderson Study Status
Enrolling
Treatment Agent
RGT-61159
Description
Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Adenoid Cystic Carcinoma, Colorectal Cancer
Study phase:
Phase I
Physician name:
Renata Ferrarotto
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-539-2756
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.